open access

Vol 93, No 12 (2022)
Research paper
Published online: 2021-11-05
Get Citation

Expression and diagnostic value of plasma protein Z and protein Z-dependent protease inhibitor in fetal growth restriction

Ci Pan1, Yulian Huang2, Xiaopei Guo2, Cunhua Gu2, Jing Guo2, Xiaohua Luo23
·
Pubmed: 35072242
·
Ginekol Pol 2022;93(12):987-992.
Affiliations
  1. Prenatal Diagnosis Center, 3rd Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  2. Department of Obstetrics and Gynecology, 3rd Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  3. Henan Provincial Clinical Research Center for Perinatal Medicine, 3rd Affiliated Hospital of Zhengzhou University, Zhengzhou, China

open access

Vol 93, No 12 (2022)
ORIGINAL PAPERS Obstetrics
Published online: 2021-11-05

Abstract

Objectives: Investigating the expression levels of plasma protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) in fetal growth restriction (FGR) and to explore their diagnostic value in FGR.

Material and methods: In this study, the number of pregnant women with FGR, healthy pregnant women (Healthy Control, HC), and childbearing-age women without pregnancy (Blank Control, BC) is 79, 79, and 60, respectively; their plasma PZ and ZPI levels in each group are determined by ELISAs. Then, the correlations between these indices and FGR were assessed using Spearman analysis. Moreover, these indices’ diagnostic values for FGR are evaluated using the receiver operating characteristics (ROC) curves.

Results: The plasma levels of PZ and ZPI are significantly decreased in the HC and FGR groups compared against the BC group (P < 0.001), whilst the levels of PZ and ZPI in the FGR groups are lower than those in the HC group (P < 0.01) notably. PZ plasma concentration has positive relationship with ZPI concentrations in the HC and FGR groups. The combination of PZ and ZPI, with the Area under the Curve (AUC) 0.92 (95% CI = 0.88–0.96), the sensitivity 0.82, and the specificity 0.88, outperforms everyone.

Conclusions: Plasma PZ and ZPI are significantly decreased in pregnant women with FGR, which can be used for pregnant women’s FGR screening.

Abstract

Objectives: Investigating the expression levels of plasma protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) in fetal growth restriction (FGR) and to explore their diagnostic value in FGR.

Material and methods: In this study, the number of pregnant women with FGR, healthy pregnant women (Healthy Control, HC), and childbearing-age women without pregnancy (Blank Control, BC) is 79, 79, and 60, respectively; their plasma PZ and ZPI levels in each group are determined by ELISAs. Then, the correlations between these indices and FGR were assessed using Spearman analysis. Moreover, these indices’ diagnostic values for FGR are evaluated using the receiver operating characteristics (ROC) curves.

Results: The plasma levels of PZ and ZPI are significantly decreased in the HC and FGR groups compared against the BC group (P < 0.001), whilst the levels of PZ and ZPI in the FGR groups are lower than those in the HC group (P < 0.01) notably. PZ plasma concentration has positive relationship with ZPI concentrations in the HC and FGR groups. The combination of PZ and ZPI, with the Area under the Curve (AUC) 0.92 (95% CI = 0.88–0.96), the sensitivity 0.82, and the specificity 0.88, outperforms everyone.

Conclusions: Plasma PZ and ZPI are significantly decreased in pregnant women with FGR, which can be used for pregnant women’s FGR screening.

Get Citation

Keywords

fetal growth restriction; protein Z; protein Z-dependent protease inhibitor; coagulation dysfunction; diagnosis

About this article
Title

Expression and diagnostic value of plasma protein Z and protein Z-dependent protease inhibitor in fetal growth restriction

Journal

Ginekologia Polska

Issue

Vol 93, No 12 (2022)

Article type

Research paper

Pages

987-992

Published online

2021-11-05

Page views

3701

Article views/downloads

532

DOI

10.5603/GP.a2021.0205

Pubmed

35072242

Bibliographic record

Ginekol Pol 2022;93(12):987-992.

Keywords

fetal growth restriction
protein Z
protein Z-dependent protease inhibitor
coagulation dysfunction
diagnosis

Authors

Ci Pan
Yulian Huang
Xiaopei Guo
Cunhua Gu
Jing Guo
Xiaohua Luo

References (24)
  1. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics and the Society forMaternal-FetalMedicin. ACOG Practice Bulletin No. 204: Fetal Growth Restriction. Obstet Gynecol. 2019; 133(2): e97–e9e109.
  2. Børte S, Winsvold BS, Stensland SØ, et al. The effect of foetal growth restriction on the development of migraine and tension-type headache in adulthood. The HUNT Study. PLoS One. 2017; 12(4): e0175908.
  3. Monk D, Moore GE. Intrauterine growth restriction--genetic causes and consequences. Semin Fetal Neonatal Med. 2004; 9(5): 371–378.
  4. Zhang S, Regnault TRH, Barker PL, et al. Placental adaptations in growth restriction. Nutrients. 2015; 7(1): 360–389.
  5. Kraus FT. Fetal thrombotic vasculopathy: perinatal stroke, growth restriction, and other sequelae. Surg Pathol Clin. 2013; 6(1): 87–100.
  6. Chui A, Zainuddin N, Rajaraman G, et al. Placental syndecan expression is altered in human idiopathic fetal growth restriction. Am J Pathol. 2012; 180(2): 693–702.
  7. Tabatabai A, Fiehler R, Broze G. Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thrombosis and Haemostasis. 2017; 85(04): 655–660.
  8. Han X, Fiehler R, Broze G. Characterization of the protein Z–dependent protease inhibitor. Blood. 2000; 96(9): 3049–3055.
  9. Huang X, Swanson R, Broze GJ, et al. Kinetic characterization of the protein Z-dependent protease inhibitor reaction with blood coagulation factor Xa. J Biol Chem. 2008; 283(44): 29770–29783.
  10. Huang X, Dementiev A, Olson ST, et al. Basis for the specificity and activation of the serpin protein Z-dependent proteinase inhibitor (ZPI) as an inhibitor of membrane-associated factor Xa. J Biol Chem. 2010; 285(26): 20399–20409.
  11. Sofi F, Cesari F, Abbate R, et al. A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost. 2010; 103(4): 749–756.
  12. Effraimidou S, Farmakiotis D, Topalidou M, et al. Low protein Z levels, but not the intron F G79A polymorphism, are associated with unexplained pregnancy loss. Thromb Res. 2009; 124(1): 24–27.
  13. Erez O, Romero R, Vaisbuch E, et al. Maternal anti-protein Z antibodies in pregnancies complicated by pre-eclampsia, SGA and fetal death. J Matern Fetal Neonatal Med. 2009; 22(8): 662–671.
  14. Bretelle F, Arnoux D, Shojai R, et al. Protein Z in patients with pregnancy complications. Am J Obstet Gynecol. 2005; 193(5): 1698–1702.
  15. Al-Shaikh FS, Sater MS, Finan RR, et al. Protein Z variants associated with protein Z plasma levels and with risk of idiopathic recurrent miscarriage. Reprod Sci. 2013; 20(9): 1062–1068.
  16. Ndour D, Gassama O. Intrauterine growth retardation, fetal growth restriction: impact on brain development. EC Paediatrics. 2019; 8: 810–819.
  17. Vasse M, Denoyelle C, Corbière C, et al. Human endothelial cells synthesize protein Z, but not the protein Z dependent inhibitor. Thromb Haemost. 2006; 95(3): 519–523.
  18. Szumowska A, Galar M, Bolkun L, et al. Plasma concentrations of protein Z and protein Z-dependent protease inhibitor in patients with essential thrombocythemia. Clin Appl Thromb Hemost. 2016; 22(7): 679–684.
  19. Huang X. Engineering a protein Z-dependent protease inhibitor (ZPI) mutant as a novel antagonist of ZPI anticoagulant function for hemophilia treatment. J Thromb Haemost. 2019; 17(10): 1655–1660.
  20. Al-Shaikh FS, Sater MS, Finan RR, et al. Protein Z variants associated with protein Z plasma levels and with risk of idiopathic recurrent miscarriage. Reprod Sci. 2013; 20(9): 1062–1068.
  21. Erez O, Hoppensteadt D, Romero R, et al. Preeclampsia is associated with low concentrations of protein Z. J Matern Fetal Neonatal Med. 2007; 20(9): 661–667.
  22. Souri M, Sugiura-Ogasawara M, Saito S, et al. Increase in the plasma levels of protein Z-dependent protease inhibitor in normal pregnancies but not in non-pregnant patients with unexplained recurrent miscarriage. Thromb Haemost. 2012; 107(3): 507–512.
  23. Quack Loetscher KC, Stiller R, Roos M, et al. Protein Z in normal pregnancy. Thromb Haemost. 2005; 93(4): 706–709.
  24. Gowri V, Mathew M, Gravell D, et al. Protein Z levels in pregnant Omani women: correlation with pregnancy outcome. J Thromb Thrombolysis. 2011; 32(4): 453–458.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl